This may change in the future to be a full diagnosis when combined with a device such as Fitbit which have blood oxygen sensors build in and awaiting FDA approval. Combining both data sets may be more of a comparison to the gold standard. But in the mean time they can market this and begin generating revenue so I can't see it as a bad thing. Could have been better yes.....but this is still positive and can be improved on down line.
RAP Price at posting:
21.0¢ Sentiment: Hold Disclosure: Held
